52nd week of 2021 patent applcation highlights part 26 |
Patent application number | Title | Published |
20210403370 | Li2O-Al2O3-SiO2-BASED CRYSTALLIZED GLASS | 2021-12-30 |
20210403371 | OPTICAL GLASS, OPTICAL ELEMENT, OPTICAL SYSTEM, INTERCHANGEABLE LENS, AND OPTICAL DEVICE - The present disclosure provides an optical glass including, by mass %, 27 to 41% of a P | 2021-12-30 |
20210403372 | GLASS CERAMIC WITH ION-CONDUCTING RESIDUAL GLASS PHASE AND PROCESS FOR THE PRODUCTION THEREOF - The present disclosure relates to a lithium ion-conducting glass ceramic which comprises a residual glass phase that is also ion-conducting, a process for the production thereof as well as its use in a battery. The glass ceramic according to the present disclosure comprises a main crystal phase which is isostructural to the NaSICon crystal phase, wherein the composition can be described with the following formula: Li | 2021-12-30 |
20210403373 | WHITE GLASS-CERAMIC SUBSTRATES AND ARTICLES INCLUDING TETRAGONAL ZIRCONIA CRYSTALLINE PHASE, AND METHOD OF MANUFACTURING THE SAME - A glass-ceramic article comprises: a center-volume composition comprising (on an oxide basis): 55-75 mol % SiO | 2021-12-30 |
20210403374 | METHOD OF MANUFACTURING OPAQUE QUARTZ GLASS - A method for manufacturing a large sized opaque quartz glass ingot having excellent heat ray shielding and light blocking properties without using a foaming agent. The obtained opaque quartz glass has small diameter spherical bubbles and a preferable mechanical strength. Silica powder is dispersed in water to form a slurry having a silica powder concentration of 45 to 75 wt % and the average particle size of the silica powder is adjusted to 8 μm or less and the standard deviation of the particle size is adjusted to 6 μm or more by wet pulverization. The slurry is sprayed for forming granules of the silica powder. An opaque quartz glass ingot with a small bubble diameter and high mechanical strength is obtained by melting the granulated silica powder. | 2021-12-30 |
20210403375 | MULTIPLE GLAZING UNIT - A multiple glazing unit having two outermost glass panes and at least one inner glass pane, where at least two intermediate gas-filled cavities each lie between two glass panes, the at least one inner glass pane bearing one metal-based insulating coating on one face and one transparent conductive oxide-based insulating coating on the opposite face, and a process for making the glazing. | 2021-12-30 |
20210403376 | GLASS-CERAMIC ARTICLE WITH SURFACE PASSIVATION LAYER AND METHODS FOR PRODUCING THE SAME - A glass-ceramic article is provided that includes a surface passivation layer. The passivation layer is an oxide layer and has a thickness of greater than or equal to 20 nm to less than or equal to 200 nm and a RMS surface roughness of less than or equal to 3 nm. The surface passivation layer may be formed with a liquid phase deposition process. The glass-ceramic article may include an easy to clean layer disposed on the surface passivation layer, and the glass-ceramic article may be chemically strengthened. The glass-ceramic article may be used in a consumer electronic product. | 2021-12-30 |
20210403377 | METHODS OF REGENERATING POISONED MOLTEN SALT BATHS WITH GLASS AND ASSOCIATED GLASS COMPOSITIONS - A method of regenerating a poisoned molten salt bath is provided. The method includes contacting glass particulates with the molten salt bath such that poisoning ions are exchanged from the bath into the glass. The glass compositions utilized in the method are also provided. | 2021-12-30 |
20210403378 | Method of Lightweight Aggregates Production from Waste-Coal Combustion Ash - Manufacturing lightweight aggregate (LWA) by a sintering technique requires a delicate balance among three conditions: forming sufficient amount of molten liquid phase during sintering; reaching an appropriate viscosity for solid-liquid suspension; and emitting sufficient amount of gas that can be entrapped by the liquid phase to form pores. LWAs were made from low-calcium and high-calcium Waste Coal Combustion Ash (W-CCA) including fly ash and bottom ash. A mass fraction of at least 40% liquid phase for fly ash and 50% for bottom ash is required for a successful entrapment of emitted gaseous phases during sintering. Larger pores were observed in the microstructure of LWA samples made using high-calcium W-CCA in comparison to low-calcium W-CCA. This result was mainly attributed to the high-calcium samples forming liquid phases with lower viscosity values and emitting higher amounts of gaseous phase during sintering than did the low-calcium samples. The gaseous phase was generated by hematite reduction and anhydrite decomposition. | 2021-12-30 |
20210403379 | LITHIUM-TREATED CALCIUM ALUMINATE CEMENT (CAC)-BASED PRODUCTS, CONCRETES, AND RELATED TECHNIQUES - Lithium-treated calcium aluminate cement (CAC)-based products, concretes, and related techniques are disclosed. In accordance with some embodiments, a lithium-treated CAC mixture may be produced by intergrinding ground-down CAC, class C fly ash, a lithium compound, and a polycarboxylate material. In accordance with some embodiments, a cementitious material may be produced by intergrinding said lithium-treated CAC mixture with class C fly ash, sodium citrate, and a polycarboxylate material. In accordance with some embodiments, a concrete may be produced by mixing said cementitious material (including said lithium-treated CAC mixture) with rock, sand, and water. | 2021-12-30 |
20210403380 | IMPROVEMENT OF THE MECHANICAL PROPERTIES OF WATERPROOFED GYPSUM BOARDS WITH POLYDIMETHYLSILOXANES - A waterproofed gypsum board and associated method are provided, featuring the use of a mixture of magnesium oxide and a gypsum crystal modifier for improving the resistance to sagging of the waterproofed gypsum board, in particular, in moist and warm climatic conditions. | 2021-12-30 |
20210403381 | IMPROVED MAGNESIUM OXYCHLORIDE CEMENT (MOC) AND A METHOD OF MANUFACTURING - A magnesium oxychloride cement (MOC) incorporating an emulsion of active cationic organo-silane and method of making same. | 2021-12-30 |
20210403382 | CERAMIC COMPLEX AND METHOD FOR PRODUCING THE SAME - A method for producing a ceramic complex includes: preparing a raw material mixture that contains 5% by mass or more and 40% by mass or less of first rare earth aluminate fluorescent material particles containing an activating element and a first rare earth element different from the activating element, 0.1% by mass or more and 32% by mass or less of oxide particles containing a second rare earth element, and the balance of aluminum oxide particles, relative to 100% by mass of the total amount of the first rare earth aluminate fluorescent material particles, the oxide particles, and the aluminum oxide particles; preparing a molded body of the raw material mixture; and obtaining a sintered body by calcining the molded body in a temperature range of 1,550° C. or higher and 1,800° C. or lower. | 2021-12-30 |
20210403383 | High Strength Shaped Aluminas and a Method of Producing Such High Strength Shaped Aluminas - A method of producing high strength shaped alumina by feeding alumina power into an agglomerator having a shaft with mixers able to displace the alumina power along the shaft, spraying a liquid binder onto the alumina power as it is displaced along the shaft to form a shaped alumina, and calcining the shaped alumina. The shaped alumina produced having a loose bulk density of greater than or equal to 1.20 g/ml, a surface area less than 10 m | 2021-12-30 |
20210403384 | METHODS OF BORONIZING SINTERED BODIES AND TOOLS FOR COLD FORMING OPERATIONS AND HOLLOW WEAR PARTS WITH BORONIZED SINTERED BODIES - Provided is a wear resistant, sintered body made of a binderless carbide, cermet or cemented carbide, e.g., WC, W | 2021-12-30 |
20210403385 | SINTERED POLYCRYSTALLINE CUBIC BORON NITRIDE MATERIAL - A method of making a polycrystalline cubic boron nitride (PCBN), material is provided. The matrix precursor powder comprises an aluminium compound. The method comprises mixing matrix precursor powder comprising particles having an average particle size no greater than 250 nm, with between 30 and 40 volume percent of cubic boron nitride (cBN) particles having an average particle size of at least 4 μm, and then spark plasma sintering the mixed particles. The spark plasma sintering occurs at a pressure of at least 500 MPa, a temperature of no less than 1050° C. and no more than 1500° C. and a time of no less than 1 minute and no more than 3 minutes. | 2021-12-30 |
20210403386 | New process for manufacturing a chromium alloyed molybdenum silicide portion of a heating element - A process of manufacturing a chromium alloyed molybdenum silicide portion of a heating element comprising the steps of: forming a mixture of a chromium powder and a silicon powder; reacting the mixture to a reaction product in an inert atmosphere at a temperature of at least 1100° C. but not more than 1580° C.; converting the reaction product to a powder comprising CrSi | 2021-12-30 |
20210403387 | ZIRCONIA SINTERED BODY AND METHOD FOR PRODUCING THE SAME - A complex sintered body includes a lamination of a layer composed of a zirconia sintered body containing 0.5% or more by mole and less than 4% by mole of an oxide of cerium in terms of CeO | 2021-12-30 |
20210403388 | SINTERING PROCESS FOR ELECTRICAL FEEDTHROUGHS - One aspect relates to a process for producing a sintered workpiece, which includes sintering of a ceramic material at a temperature of at least 1000° C. and in an atmosphere, in the case of which the partial pressure of atmospheric air is reduced to less than 10 | 2021-12-30 |
20210403389 | APPLYING SILICON METAL-CONTAINING BOND LAYER TO CERAMIC OR CERAMIC MATRIX COMPOSITE SUBSTRATES - In some examples, a method may include depositing, from a slurry comprising particles including silicon metal, a bond coat precursor layer including the particles comprising silicon metal directly on a ceramic matrix composite substrate. The method also may include locally heating the bond coat precursor layer to form a bond coat comprising silicon metal. Additionally, the method may include forming a protective coating on the bond coat. In some examples, an article may include a ceramic matrix composite substrate, a bond coat directly on the substrate, and a protective coating on the bond coat. The bond coat may include silicon metal and a metal comprising at least one of Zr, Y, Yb, Hf, Ti, Al, Cr, Mo, Nb, Ta, or a rare earth metal. | 2021-12-30 |
20210403390 | METHOD OF TREATING CERAMICS AND CERAMIC MEMBER - A ceramic member is produced by performing a laser treatment on a ceramic substrate as a pretreatment for a surface treatment such that grooves that can be substantially uniformly filled with a surface treatment material are formed in the surface of the ceramic substrate. Through laser irradiation of the surface grooves with recessed surfaces formed to extend in at least one direction are provided. Flat surfaces are formed at areas between the grooves that are adjacent to each other. Pitches between the adjacent grooves are set to a range of 0.05 mm to 0.30 mm. One of the grooves has a width that progressively decreases as the depth increases and is opened on one side in the depth direction at a maximum width. The one of the grooves has an aspect ratio in a range of 0.5 to 1.3 and an opening ratio of equal to or greater than 70%. | 2021-12-30 |
20210403391 | ROTTING METHOD AND DEVICE FOR AN ORGANIC MATERIAL - A method for rotting an organic material includes at least partially controlling a rotting device with a control unit and feeding an organic material into a pivoted rotting chamber of the rotting device, having the organic material rotted in the rotting chamber for a rotting time, turning the rotting chamber by a chamber drive unit of the rotting device, and exhausting the rotted organic material from the rotting chamber after the rotting time. A device for rotting the organic material includes a pivoted rotting chamber for enclosing the organic material. The rotting chamber has a port and a cover associated with the port for opening and closing the port, a chamber drive unit configured to turn the rotting chamber, and a control unit connected to the chamber drive unit and configured to operate the chamber drive unit. | 2021-12-30 |
20210403392 | MICROALGAE-BASED SOIL NON-ELECTRIC INOCULATING SYSTEM AND METHODS OF USE - Some embodiments include a microalgae culturing system including a bioreactor adapted to propagate microalgae in a culture solution using in combination at least one of natural and artificial light, and at least one nutrient including at least a carbon source, where the microalgae are freely suspended in and form part of the culture solution. A microalgae feed source is coupled to the bioreactor and a first controller between a water conditioning assembly and the bioreactor. The water conditioning assembly is coupled as an input of supply water to the bioreactor, and configured to condition the supply water to a specified purity that enables substantially unhindered growth of the microalgae in the culture solution to a specified concentration, and the first controller is configured to control supply of the microalgae feed source to the bioreactor. | 2021-12-30 |
20210403393 | COMPOSITION CONTAINING N-(N-BUTYL) THIOPHOSPHORIC TRIAMIDE ADDUCTS AND REACTION PRODUCTS - Reaction products and methods for making and using such reaction products are provided. For example, a reaction product comprising an adduct formed from urea, formaldehyde, and a urease inhibitor is described, which can be provided in various forms. For example, such a reaction product can be in the form of a solid or solution. Such a reaction product can also be combined with one or more additional components, including but not limited to, additional urease inhibitor and/or a nitrogen-based fertilizer composition. | 2021-12-30 |
20210403394 | Lubricated Agricultural Mixture - A lubricated agricultural mixture and method(s) of use thereof is described. Embodiments of the lubricated agricultural mixture can include a carbon source, a fertilizer, a binder, and a hydrogel. The lubricated agricultural mixture can be formed into tablets, granules, and wafers. The different forms of the lubricated agricultural mixture can be implemented in various situations. For instance, the table form can be distributed via machinery such that the carbon source acts as a lubricant for the machinery to minimize wear on the machinery. | 2021-12-30 |
20210403395 | METHOD FOR PRODUCING OXIDATION REACTION PRODUCT OF HYDROCARBON OR DERIVATIVE THEREOF - The present invention is intended to provide a method that can produce an oxidation reaction product of a hydrocarbon or a derivative thereof in an aqueous phase using a hydrocarbon or a derivative thereof as a raw material. In order to achieve the above object, the method for producing an oxidation reaction product of a hydrocarbon or a derivative thereof of the present invention includes the step of: irradiating a reaction system with light in a presence of a raw material and a halogen oxide radical to react, wherein the raw material is a hydrocarbon or a derivative thereof, the reaction system is a reaction system containing an aqueous phase, the aqueous phase contains the raw material and the halogen oxide radical, and in the reaction step, the raw material is oxidized to produce an oxidation reaction product of the raw material. | 2021-12-30 |
20210403396 | ISOBUTYLENE TO PROPYLENE PROCESS FLOW IMPROVEMENT - Improved systems and methods for producing propylene from olefins including isobutylene is disclosed. The improvements combine streams containing co-produced 1-butene, 2-butene, butadiene, and heavy olefins (C5+) exiting both a metathesis reactor and a skeletal isomerization reactor in a gasoline fractionation tower to remove the heavy olefins. The C4-containing distillate from the gasoline fractionation tower is then fed to a hydroisomerization unit to form mono-olefins and 2-butene. The resulting 2-butene rich stream can then be utilized in metathesis reactions to increase the production of propylene while increasing the lifetime of the metathesis catalyst. | 2021-12-30 |
20210403397 | METHOD AND SYSTEM TO CONTROL AND MAINTAIN PRODUCT QUALITY FOR AN OLEFIN MEMBRANE SEPARATION - A process and system to control the final product quality in a system for separating olefins and paraffins in a membrane system. A small finishing membrane stage is added to an existing membrane system that takes a slip stream from the product, purifies it to a very high concentration of propylene and blends it back into the product stream. | 2021-12-30 |
20210403398 | PROCESS FOR THE CONTROLLED OLIGOMERIZATION OF BUTENES - The selective dimerization of isoolefins, such as isobutene or isopentane, or mixtures thereof, may be conducted in a system including a series of fixed bed reactors and a catalytic distillation reactor. The system may provide for conveyance of the fixed bed reactor effluents, without componential separation, to a downstream reactor. It has been found that a high selectivity to the dimer may be achieved even though intermediate separation of the desired product from unreacted components between reactors is not performed. Further, embodiments provide for use of a divided wall column for recovery of a high purity dimer product, reducing unit piece count and plot size. | 2021-12-30 |
20210403399 | METHOD FOR PRODUCING DIFLUOROETHYLENE - Provided is a method for obtaining HFO-1132(E) and/or HFO-1132(Z) efficiently. The method is a method for producing HFO-1132(E) and/or HFO-1132(Z), comprising supplying a composition containing HFO-1132(E) and/or HFO-1132(Z) to a reactor, and performing an isomerization reaction between HFO-1132(E) and HFO-1132(Z). | 2021-12-30 |
20210403400 | ION-EXCHANGE RESIN CORE-SHELL CATALYST PARTICLES - The invention is directed to a catalyst, to a method for manufacturing a catalyst, to a method for manufacturing a bisphenol compound, and to the use of a catalyst. The catalyst of the invention comprises particles having a core and a shell, wherein the shell comprises an ion exchange resin covering the core at least in part and wherein the core has a density that is higher than the density of the ion exchange resin. | 2021-12-30 |
20210403401 | METHODS OF ISOLATING PHENOLS FROM PHENOL-CONTAINING MEDIA - Methods of isolating phenols from phenol-containing media. The methods include combining a phospholipid-containing composition with the phenol-containing medium to generate a combined medium, incubating the combined medium to precipitate phenols in the combined medium and thereby form a phenol precipitate phase and a phenol-depleted phase, and separating the phenol precipitate phase and the phenol-depleted phase. The methods can further include extracting phenols from the separated phenol precipitate phase. The extracting can include mixing the separated phenol precipitate phase with an extraction solvent to solubilize in the extraction solvent at least a portion of the phenols originally present in the phenol precipitate phase. | 2021-12-30 |
20210403402 | FLUORINATED ETHER COMPOUND, FLUORINATED ETHER COMPOSITION, COATING LIQUID, ARTICLE AND ITS PRODUCTION METHOD - To provide a fluorinated ether compound capable of forming a surface layer excellent in initial water/oil repellency, fingerprint stain removability, abrasion resistance and light resistance; a fluorinated ether composition and a coating liquid containing the fluorinated ether compound; an article having a surface layer excellent in initial water/oil repellency, fingerprint stain removability, abrasion resistance and light resistance and a method for producing it. A fluorinated ether compound having a poly(oxyperfluoroalkylene) chain having a unit (a) which is an oxyperfluoroalkylene unit having 5 or 6 carbon atoms, and a unit (P) which is an oxyperfluoroalkylene unit having at most 4 carbon atoms, and having at least one of a hydrolysable silyl group and a silanol group on at least one terminal of the poly(oxyperfluoroalkylene) chain via a linking group. | 2021-12-30 |
20210403403 | PROCESS FOR PREPARING (9Z,11E)-9,11-HEXADECADIENAL - The present invention provides a process for preparing (9Z,11E)-9,11-hexadecadienal of the following formula (4), the process comprising: subjecting (2E)-2-heptenal of the following formula (1) to a Wittig reaction with a triarylphosphonium 9,9-dialkoxynonylide compound of the following general formula (2), wherein Ar represents an aryl group that may be same with or different from each other, and R | 2021-12-30 |
20210403404 | PROCESS FOR PREPARING METHACROLEIN - Provided is a process for preparing dry methacrolein which maximizes capture of methanol. Also provided is a process for producing methyl methacrylate. | 2021-12-30 |
20210403405 | ADDITION CONDENSATION PRODUCT, PRODUCTION METHOD AND USE OF SAME, POLYMERIZATION VESSEL, AND PRODUCTION METHOD OF POLYMER - Provided is an addition condensation product of an aromatic compound and a carbonyl compound. The addition condensation product includes an aromatic compound dimer in which two composition units derived from the aromatic compounds are bonded via one composition unit derived from the carbonyl compound and an aromatic compound multimer in which each of three or more composition units derived from the aromatic compounds is bonded via one composition unit derived from the carbonyl compound. A ratio of the aromatic compound dimer to the aromatic compound multimer is in the range of 1:75 to 1:1,000. | 2021-12-30 |
20210403406 | PROCESS FOR PREPARING 2,6-DIALKYLPHENYLACETIC ACIDS - The invention relates to a multi-stage process for preparing 2,6-dialkylphenylacetic acids of the general formula (I) by reacting 2,6-dialkylbromobenzenes with (1) magnesium, (2) a formamide, (3) an acid, (4) hydrogenation of the benzaldehyde obtained, (5) activation of the benzyl alcohol obtained, (6) cyanation of the activated benzyl alcohol and (7) hydrolysis of the nitrile obtained. | 2021-12-30 |
20210403407 | 4-HYDROXYBUTYRIC ACID ANALOGS - This invention relates to novel derivatives of 4-hydroxybutyric acid and prodrugs thereof, and pharmaceutically acceptable salts of the foregoing. This invention also provides pharmaceutical compositions comprising a compound of this invention and the use of such compositions in methods of treating narcolepsy, fibromyalgia, other disorders or conditions that are beneficially treated by improving nocturnal sleep or by administering sodium oxybate. | 2021-12-30 |
20210403408 | CANNABINOID ANALOGS AND METHODS FOR THEIR PREPARATION - Provided herein are cannabinoid analogs, including halogenated cannabinoid analogs, hydroxylated cannabinoid analogs, deuterated cannabinoid analogs, and tritiated cannabinoid analogs. The cannabinoid analogs can be prepared by partial or total expression in modified host cells, such as recombinantly modified yeast cells, optionally in combination with chemical synthetic steps. | 2021-12-30 |
20210403409 | METHOD FOR PRODUCING CARBONATE DERIVATIVE - The objective of the present invention is to provide a method for producing a polycarbonate safely and efficiently even without using a base. The method for producing a carbonate derivative according to the present invention is characterized in comprising the step of irradiating a high energy light to a composition comprising the halogenated methane and the hydroxy group-containing compound in the presence of oxygen, wherein a molar ratio of a total usage amount of the hydroxy group-containing compound to 1 mole of the halogenated methane is 0.05 or more. | 2021-12-30 |
20210403410 | OPHTHALMIC FORMULATION - Disclosed herein is an ophthalmic formulation comprising a compound of formula (I) wherein le is a linear or branched C | 2021-12-30 |
20210403411 | METHOD FOR PRODUCING AMINE THROUGH REDUCTION OF AMIDE - The present invention provides a method for producing primary amines and secondary amines, the method being characterized by reducing a primary amide or a secondary amide in the presence of a reducing agent and an organic metal halide of a group-2 element. | 2021-12-30 |
20210403412 | PRODUCTION OF NITROGEN-CONTAINING CHELATORS - Reaction pathways and conditions for the production of nitrogen-containing chelators, such as a glycine derivative, are described herein. In particular, the present disclosure describes a process for the production of a nitrile intermediate at a high yield and/or purity. This process includes reacting a dinitrile compound with an aldehyde and a hydrogen cyanide to form the nitrile intermediate. The nitrile intermediate may then be further processed to produce the chelators at a high yield and/or a high purity. | 2021-12-30 |
20210403413 | PRODUCTION OF NITROGEN-CONTAINING CHELATORS - Reaction pathways and conditions for the production of nitrogen-containing chelators, such as a glycine derivative, as described herein. In particular, the present disclosure describes a process for the production of a nitrile intermediate by reacting a tetra-amino compound with an aldehyde and a hydrogen cyanide to form the nitrile intermediate. The nitrile intermediate may then be further processed to produce the chelators at a high yield and/or a high purity. | 2021-12-30 |
20210403414 | PRODUCTION OF NITROGEN-CONTAINING CHELATORS - Reaction pathways and conditions for the production of nitrogen-containing chelators, such as a glycine derivative, are described herein. In particular, the present disclosure describes a process for the production of a nitrile intermediate by reacting a tetra-amino compound with an aldehyde and a hydrogen cyanide to form the nitrile intermediate. The nitrile intermediate may then be further processed to produce the chelators at a high yield and/or a high purity. | 2021-12-30 |
20210403415 | COMPOUNDS AND METHODS TO ATTENUATE TUMOR PROGRESSION AND METASTASIS - This invention relates to certain compounds or pharmaceutically acceptable salts thereof, and for the use of the compounds to treat cancer. In another aspect, the disclosure relates to a pharmaceutical composition comprising a compound of Formula (1), Formula (1a), or Formula (1b), or a pharmaceutically acceptable salt thereof, and at least one of a pharmaceutically acceptable carrier, diluent or excipient. | 2021-12-30 |
20210403416 | Novel Modified Tetracyclines for Treatment of Alcohol Use Disorder, Pain and Other Disorders Involving Potential Inflammatory Processes - The present invention includes novel molecules and methods for using the same to treat Alcohol Use Disorder (AUD), Substance Use Disorder (SUD), tobacco use, pain, or proinflammatory disorders comprising: identifying a subject in need of treatment for at least one of AUD, SUD, pain, or a proinflammatory disorder; and providing the subject with an effective amount of a modified minocycline to ameliorate or eliminate the AUD, SUD, pain, or proinflammatory disorder and that has reduced, or no, antimicrobial activity, wherein the modified tetracycline has a formula, e.g., or the modified doxycycline, minocycline, and tigecycline and their tautomerized structures, where the R-groups shown in the minocycline example above could be different combination of halogen, acetyl ester, methyl ester, and diacetal. | 2021-12-30 |
20210403417 | PROCESS FOR PREPARING DIISOCYANATES BASED ON LYSINE - The invention relates to a process for preparing a diisocyanate of the formula (A) | 2021-12-30 |
20210403418 | METHOD FOR REMOVING MONOISOCYANATES FROM ORGANIC SOLUTION - Monoisocyanate impurities are removed from a process stream obtained when solvent is separated from a polyisocyanate product. The monoisocyanates are reacted with amine compounds at specific molar ratios to produce ureas. The ureas can be discarded by burning, landfilling or otherwise. Alternatively the ureas can be recycled back into the polyisocyanate manufacturing process, where they are formed into biuret compounds that can remain with the polyisocyanate product. | 2021-12-30 |
20210403419 | SERINE DERIVATIVE COMPOUND FOR THE PREVENTION OR TREATMENT OF CENTRAL NERVOUS SYSTEM DISEASES - The present invention relates to a serine derivative compound having improved blood-brain barrier (BBB) permeability and the use thereof, and more particularly, to a novel serine derivative compound having improved blood-brain barrier permeability compared to L-serine, and a pharmaceutical composition for preventing, treating or alleviating nervous system diseases such as cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, the pharmaceutical composition containing the compound as an active ingredient. The compound of Formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient for the pharmaceutical composition for preventing or treating central nervous system diseases according to the present invention exhibits significantly improved blood-brain barrier permeability, activates neuronal cell proliferation, and exhibits a neuronal protective effect of inhibiting neuronal cell death resulting from mitochondrial membrane potential damage and/or endoplasmic reticulum stress caused by oxidative stress, and exhibits improved blood-brain barrier permeability. Therefore, the compound has an excellent effect on the prevention, treatment and alleviation of central nervous system diseases such as cognitive disorder, intellectual disability, microcephaly, epilepsy, neurodevelopmental disorder, dementia, autism spectrum disorder, Down's syndrome, Rett's syndrome, fragile X syndrome, Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis, and thus is a highly useful invention in the pharmaceutical industry, the food industry and the livestock industry. | 2021-12-30 |
20210403420 | BENZOATE COMPOUND - The present invention provides a benzoic acid ester compound that has an enteropeptidase inhibitory effect, and use of the compound as a medicament for the treatment or prevention of obesity, diabetes mellitus, or the like. | 2021-12-30 |
20210403421 | BIODEGRADABLE SURFACTANTS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS - Biodegradable surfactants are described, in which an amphiphilic heteroatom containing hydrocarbon optionally comprising at least one counterion (Z), and related compositions, methods and systems. Biodegradable surfactant described herein has an aHLB value in accordance with equation (1): aHLB=20*Gh/(Gh−Gt) (1) wherein Gh is the Group Number of a hydrophilic head portion of the biodegradable surfactant optionally comprising the at least one counterion (Z), and Gt is the Group Number of a hydrophobic tail portion of the biodegradable surfactant. A biodegradable surfactant in the sense of the disclosure can be tuned to a set hydrophilic-lipophilic balance (aHLB) by selectively modifying at least one tuning moiety of the biodegradable surfactants to provide tuned biodegradable surfactants having an increase or decrease in their adjusted hydrophilic-lipophilic balance (aHLB). | 2021-12-30 |
20210403422 | ALKOXYLATED SECONDARY ALCOHOL SULFATES - The invention relates to compounds of formula (I), | 2021-12-30 |
20210403423 | OXYGEN SCAVENGING MOLECULES, ARTICLES CONTAINING SAME, AND METHODS OF THEIR USE - The invention relates to compounds of the structure of formula I and II: | 2021-12-30 |
20210403424 | BIOACTIVE PHYTOCHEMICALS IN ZIZYPHUS AND GUARANA - Described are compositions comprising selected isolated 4-hydroxymethyl-prolines, or pharmaceutically acceptable salts or derivatives thereof. Also described are novel 4-hydroxymethyl-N-methyl-prolines, together with processes for their preparation, compositions containing them, as well as their use as medicaments and pharmaceuticals. Also described are processes for producing a herbal medicine comprising the step of monitoring the quality of said herbal medicine by detecting the presence or absence or measuring the amount of one or more 4-hydroxymethyl-N-methyl-prolines in a sample of said herbal medicine. | 2021-12-30 |
20210403425 | TRYPTAMINE PRODRUGS - The present invention provides a tryptamine prodrug compound. A compound represented by the formula (I) | 2021-12-30 |
20210403426 | DEUTERATED N,N-DIMETHYLTRYPTAMINE COMPOUNDS - Compounds, compositions, methods, and uses are described for therapeutic deuterated N,N-dimethyltryptamine compounds (e.g., a single compound or a plurality of deuterated N,N-dimethyltryptamine compounds) such as N,N-dimethyltryptamine compounds, α-protio, α-deutero-N,N-dimethyltryptamine compounds, α,α-dideutero-N,N-dimethyltryptamine compounds, and pharmaceutically acceptable salts of these compounds. The deuterated N,N-dimethyltryptamine compound may have an increased half-life compared with the half-life of undeuterated N,N-dimethyltryptamine. For example, a deuterated N,N-dimethyltryptamine compound may be used in therapy and have a Formula (I): | 2021-12-30 |
20210403427 | METHOD FOR PRODUCING AMINO ACID DERIVATIVES - The present invention aims to provide a method for producing a (2S,5R)-5-(protected oxyamino)-piperidine-2-carboxylic acid derivative at a low cost that can be performed under mild reaction conditions not requiring a facility at an extremely low temperature, is safer, can control the quality of the desired product with ease, and shows good workability in the site of production. A method for producing a compound represented by the formula (2): | 2021-12-30 |
20210403428 | CRYSTAL FORMS OF 2-[4-[(2,3,4-TRIMETHOXPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE - The invention provides polymorphs of a compound of Formula (X): | 2021-12-30 |
20210403429 | METHODS OF SYNTHESIZING 2-[4-[(2,3,4-TRIMETHOXYPHENYL)METHYL]PIPERAZIN-1-YL]ETHYL PYRIDINE-3-CARBOXYLATE - The invention provides methods of chemical synthesis of the pharmacological agent 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate, also called CV-8972. The methods entail formation of a free base form of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethanol, also called CV-8814, as intermediate without producing a salt form of CV-8814. | 2021-12-30 |
20210403430 | Polycationic Amphiphiles as Antimicrobial Agents and Methods Using Same - The present invention includes novel polycationic amphiphilic compounds useful as antimicrobial agents. The present invention further includes methods useful for removing microorganisms and/or biofilm-embedded microorganisms from a surface. The present invention further includes compositions and methods useful for preventing or reducing the growth or proliferation of microorganisms and/or biofilm-embedded microorganisms on a surface. | 2021-12-30 |
20210403431 | PROCESS FOR THE PREPARATION OF N-(4-(6,7-DIMETHOXYQUINOLIN-4-YLOXY) PHENYL)-N'-(4-FLUOROPHENYL)CYCLOPROPANE-1, 1-DICARBOXAMIDE, (2S)-HYDROXYBUTANEDIOATE AND ITS POLYMORPHS THEREOF - The present invention also relates to process for the preparation of N-(4-(6,7-dimethoxy quinolin-4-yloxy)phenyl)-N′-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (S)-malate compound of formula-1a and its polymorphs thereof, represented by the following structural: | 2021-12-30 |
20210403432 | COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING METABOLIC DISEASES AND/OR A CLINICAL CONDITION THEREOF - Therapeutic compositions comprising one or more agents that inhibit CXXC5-DVL interface, and methods of administering those therapeutic compositions to model, treat, reduce resistance to treatment, prevent, and diagnose a condition/disease associated with a metabolic disease or a related clinical condition thereof, are disclosed. | 2021-12-30 |
20210403433 | FUSED PIPERIDINYL BICYCLIC AND RELATED COMPOUNDS AS MODULATORS OF C5A RECEPTOR - The present invention relates to fused piperidinyl bicyclic, meta-substituted piperidinyl and their related compounds that modulate activities of mammalian C5a receptor by directly binding to the C5a receptor. The invention also relates to pharmaceutical compositions containing such compounds and their use in the treatment of a disease or a disorder involving pathogenic activation of C5a receptors. | 2021-12-30 |
20210403434 | METABOLICALLY STABLE 5-HMF DERIVATIVES FOR THE TREATMENT OF HYPOXIA - 5-HMF derivative compounds that bind covalently with hemoglobin are provided. Methods of treating sickle cell disease and other hypoxia-related disorders by administering such compounds are also provided. | 2021-12-30 |
20210403435 | HERBICIDAL COMPOUNDS - Use of the compounds of the formula (I) wherein the substituents are as defined herein as herbicides. Compounds of formula (I) are also claimed. | 2021-12-30 |
20210403436 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING DISEASES - The present application is directed, in part, to compounds, and/or pharmaceutically acceptable salts or solvates thereof, and/or pharmaceutical compositions thereof, for modulating the activity of Sigmal receptor. The present application is further directed, in part, to methods for treating and/or preventing cancer using compounds disclosed herein, and/or pharmaceutically acceptable salts or solvates thereof, and/or pharmaceutical compositions thereof. | 2021-12-30 |
20210403437 | METHODS OF SELECTIVELY FORMING SUBSTITUTED PYRAZINES - Methods of selectively forming substituted pyrazines are provided. Methods of the present invention can include receiving a reaction solution including at least one carbon source and at least one nitrogen source, and heating the reaction solution to a reaction temperature and holding the reaction solution at the reaction temperature for a time sufficient to produce a reaction product comprising at least one substituted pyrazine. The carbon source can be selected from the group consisting of hydroxy ketone(s), sugar(s) treated with at least one buffer, and combinations thereof. Tobacco products incorporating substituted pyrazines are also provided. | 2021-12-30 |
20210403438 | CURABLE COMPOSITION, CURED PRODUCT, OPTICAL MEMBER, LENS, AND METHOD FOR MANUFACTURING OPTICAL MEMBER - A curable composition containing a compound represented by General Formula A and a salt of an acidic phosphoric acid ester is provided as a curable composition for forming a cured product that has a small Abbe number and a large partial dispersion ratio and has excellent moldability. | 2021-12-30 |
20210403439 | TRIAZOLE GLYCOLATE OXIDASE INHIBITORS - The present invention provides triazole carboxylic acids and related compounds, as well as pharmaceutically acceptable salts thereof, which are useful as glycolate oxidase inhibitors. Pharmaceutical compositions and methods for treating primary hyperoxaluria, type I (PH) and kidney stones are also described. | 2021-12-30 |
20210403440 | SUBSTITUTED TOLYL FUNGICIDES - Disclosed are compounds of Formula 1, including all geometric and stereoisomers, tautomers, N-oxides, and salts thereof, | 2021-12-30 |
20210403441 | FUNCTIONAL GROUP-PROTECTED DIAZIDOGLYOXIME, METHOD OF SYNTHESIZING THE SAME, AND METHOD OF SYNTHESIZING TKX-50 USING FUNCTIONAL GROUP-PROTECTED DIAZIDOGLYOXIME - The present invention relates to functional group-protected diazidoglyoxime (DAG), a method of synthesizing the same, and a method of synthesizing TKX-50 using functional group-protected DAG. Insensitive-DAG with enhanced insensitivity, instead of sensitive DAG, may be synthesized to reduce risks of processes and harmfulness arising from threats of explosion and fire accidents caused by impact, friction and static electricity, and thus it is possible to stably synthesize functional group-protected DAG. | 2021-12-30 |
20210403442 | Novel formulation of metaxalone - The present invention relates to methods for producing particles of metaxalone using dry milling processes as well as compositions comprising metaxalone, medicaments produced using metaxalone in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of metaxalone administered by way of said medicaments. | 2021-12-30 |
20210403443 | SUBSTITUTED 1,2,4-OXADIAZOLE, ITS APPLICATION AND A PHARMACEUTICAL PREPARATION COMPRISING IT - Disclosed are compounds effective against tuberculosis based on substituted 1,2,4-oxadiazoles of general formula I, where Y═S or CH | 2021-12-30 |
20210403444 | HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF RSV - Disclosed herein are compounds and compositions for treating or inhibiting RSV and related members of the pneumovirus and paramyxovirus families such as human metapneumovirus, mumps virus, human parainfluenzaviruses, and Nipah and hendra virus, and methods of treatment or prevention thereof. | 2021-12-30 |
20210403445 | SYSTEMS AND METHODS FOR REGIOSELECTIVE CARBONYLATION OF 2,2-DISUBSTITUTED EPOXIDES - Provided are methods of carbonylating cyclic substrates to produce carbonylated cyclic products. The cyclic substrates may be 2, 2-di substituted epoxides and the cyclic products may be β,β-di substituted lactones. The method may be carried out by forming and pressurizing a reaction mixture of the cyclic substrate, a solvent, carbon monoxide, and a [LA | 2021-12-30 |
20210403446 | INTEGRATED METHODS FOR CHEMICAL SYNTHESIS - The integrated processes herein provide improved carbon efficiency for processes based on coal or biomass gasification or steam methane reforming. Provided are also ethylene oxide carbonylation products such as beta-propiolactone and succinic anhydride having a bio-based content between 0% and 100%, and methods for producing and analyzing the same. | 2021-12-30 |
20210403447 | PROCESS FOR PREPARING DIOXOLANE - The present invention relates to a process for preparing dioxolane by reacting ethylene glycol with an aqueous solution of formaldehyde in the presence of an acid catalyst. The raw product comprising water, dioxolane and methanol is fed to a phase separation unit ( | 2021-12-30 |
20210403448 | Niraparib Compositions - The present invention relates to compositions comprising the compound niraparib, in particular certain solid forms of niraparib. | 2021-12-30 |
20210403449 | BIPHENYL DIARYL PYRIMIDINE DERIVATIVE WITH AROMATIC HETEROCYCLIC STRUCTURE - This application provides a biphenyl diaryl pyrimidine derivative with an aromatic heterocyclic structure, a pharmaceutically-acceptable salt, a stereoisomer, a hydrate and a solvate thereof, where the biphenyl diaryl pyrimidine derivative is shown in formula (I). This application also provides a pharmaceutical composition containing the biphenyl diaryl pyrimidine derivative, or a pharmaceutically-acceptable salt, a stereoisomer, a hydrate and a solvate thereof, and a pharmaceutically-acceptable carrier. This application further provides a method of treating AIDS by administering a therapeutically effective amount of the pharmaceutical composition to a patient in need. | 2021-12-30 |
20210403450 | CRYSTAL FORM A OF NHE3 INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF - Provided is crystal form A of N, N′-(10, 17-dioxo-3, 6, 21, 24-tetraoxa-9, 11, 16, 18-tetrazohexahexane-1, 26-di-yl)bis(4-(6, 8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinoline-4-yl) benzene sulfonamide. The crystal form has good light stability, high-temperature stability, and high-humidity stability. | 2021-12-30 |
20210403451 | PYRIMIDOPYRAZOLONE DERIVATIVE AS WEE1 INHIBITOR AND USE THEREOF - A pyrimidopyrazolone derivative as a Wee1 inhibitor and use thereof in preparation of a medicament for treating Wee1-related diseases are described. In particular, the present invention relates to a compound of formula (I), an isomer or a pharmaceutically acceptable salt thereof. | 2021-12-30 |
20210403452 | SOLID FORMS OF 2-METHYL-1-[(4-[6-(TRIFLUOROMETHYL) PYRIDIN-2-YL]-6-{[2-(TRIFLUOROMETHYL)PYRIDIN-4-YL]AMINO}-1,3,5-TRIAZIN-2-- YL) AMINO]PROPAN-2-OL - Solid forms comprising 2-methyl-1-[(4-[6-(trifluoromethyl)pyridin-2-yl]-6-{[2-(trifluoromethyl)pyridin-4-yl] amino-1,3,5-triazin-2-yl)amino]propan-2-ol, compositions comprising the solid forms, methods of making the solid forms and methods of using the solid forms are disclosed. | 2021-12-30 |
20210403453 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH - Provided herein are piperidine dione compounds having the following structure: | 2021-12-30 |
20210403454 | CEREBLON BINDING COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH - Provided herein are piperidine dione compounds having the following structure: | 2021-12-30 |
20210403455 | FLUORINE-CONTAINING PYRIMIDINE COMPOUND AND METHOD FOR MANUFACTURING THE SAME - A fluorine-containing pyrimidine compound is provided represented by general formula (1), (2), (3), (4), (5), or (6) below. | 2021-12-30 |
20210403456 | HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF EPILEPSY - The present invention provides a novel heterocyclic compound represented by Formula [I] and a salt thereof: | 2021-12-30 |
20210403457 | 2-OXOIMIDAZOLIDINE-4-CARBOXAMIDES AS NAV1.8 INHIBITORS - Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are inhibitors of Na | 2021-12-30 |
20210403458 | Brefeldin A Derivatives, Preparation Method and Use thereof - The present disclosure relates to the field of medicinal chemistry, and specifically to brefeldin A derivatives represent by Formula (I) and its use in the inhibition of tumor proliferation activity. The new compounds provided herein are prominent in the prevention or treatment of hyperproliferative diseases, including liver cancer, leukemia, breast cancer, colon adenocarcinoma, lung cancer, Bart's esophageal cancer, gastric cancer, cervical cancer, pancreatic cancer, kidney cancer, endometrial cancer, nasopharyngeal cancer, bone cancer, lymphoma, brain cancer, nerve cancer, oral cancer and colorectal cancer, and have the potential to be developed as novel antitumor agents. | 2021-12-30 |
20210403459 | SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOF - The invention generally relates to substituted benzofuranyl and substituted benzoxazolyl compounds, and more particularly to a compound represented by Structural Formula A: | 2021-12-30 |
20210403460 | INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF - The invention provides novel chemical compounds useful for treating cancer, or a related disease or disorder thereof, and pharmaceutical composition and methods of preparation and use thereof. | 2021-12-30 |
20210403461 | OXADIAZOLE COMPOUND AND FUNGICIDE FOR AGRICULTURAL AND HORTICULTURAL USE - This fungicide for agricultural and horticultural use includes a compound represented by formula (I) (in the formula, X represents a halogen group, or the like; n represents any integer of 0 to 4; when n is 2 or more, X may be the same or different; L represents a single bond or a substituted or unsubstituted C1-6 alkylene group; Q is a group represented by formula (Q-1) or formula (Q-2) (in the formulae, * represents a binding site; Y | 2021-12-30 |
20210403462 | PESTICIDALLY ACTIVE AZOLE-AMIDE COMPOUNDS - Compounds of formula I wherein the substituents are as defined in claim | 2021-12-30 |
20210403463 | OXAZOLIDINONE COMPOUNDS, LIPOSOME COMPOSITIONS COMPRISING OXAZOLIDINONE COMPOUNDS AND METHOD OF USE THEREOF - Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections. | 2021-12-30 |
20210403464 | CRYSTALLINE FORMS OF DEUTERIUM-ENRICHED PIOGLITAZONE - Provided herein are crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof. Also provided herein are methods of using the crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof. | 2021-12-30 |
20210403465 | QUINAZOLINYL-INDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION - Compounds of Formula I, including pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth: | 2021-12-30 |
20210403466 | TRICYCLIC COMPUND AS CRTH2 INHIBITOR - Provided are a tricyclic compound as shown in formula (I) as a CRTH2 inhibitor, or a pharmaceutically acceptable salt, a tautomer, a stereoisomer or a solvate thereof, and the use thereof in treating diseases related to CRTH2 receptors. | 2021-12-30 |
20210403467 | APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES - Disclosed herein are compounds that inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases using the compounds. | 2021-12-30 |
20210403468 | SUBSTITUTED INDOLE AND INDAZOLE COMPOUNDS - Disclosed are compounds of Formula (I) N-oxides, or salts thereof, wherein X is CR | 2021-12-30 |
20210403469 | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS AS INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS - Disclosed herein are compounds of formula (I) which are inhibitors of an IDO enzyme: Formula (I). Also disclosed herein are uses of the compounds in the potential treatment or prevention of an IDO-associated disease or disorder. Also disclosed herein are compositions comprising these compounds. Further disclosed herein are uses of the compositions in the potential treatment or prevention of an IDO-associated disease or disorder. | 2021-12-30 |